Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

U.S. District Judge Mark Pittman in Texas denied compounders' bid for a preliminary injunction, according to the court docket ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual ... make Novo Europe's most valuable listed company worth $615 billion at its peak.